SUBSEQUENT EVENTS	12 Months Ended
Dec. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS In August 2019, in accordance with the Federal Food, Drug, and Cosmetic Act, or the Act, the Company paid a fee of $2.6 million to the FDA under the Prescription Drug User Fee Act in conjunction with the filing of its NDA for veverimer. The Company filed a request with the FDA to grant a waiver and refund of the application fee under the small business waiver provision of the Act. Due to the uncertainty regarding the collectability of this refund, the Company recorded this filing fee as a research and development expense in the quarter ended September 30, 2019. In January 2020, the FDA granted the Company’s request for a waiver and refunded the application fee in February 2020. The refund will be recorded as a gain in research and development expense for the three months ending March 31, 2020.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration